PIK3CA and breast cancer: These results led to a phase III study, the SANDPIPER trial, for PIK3CA-mutant advanced HR+/HER2− BC resistant to ET, evaluating fulvestrant associated with taselisib (n = 430) versus placebo (n = 176).